ArticleFrontiers in cell and developmental biology2026
Thrombin dynamics and clinical events in cirrhosis: low prothrombin conversion predicts bleeding risk.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pro- and anti-coagulant factors are significantly altered in liver cirrhosis resulting in an increased bleeding and thrombosis risk. The thrombin generation (TG) test often seems unaltered in cirrhosis, indicating that a new hemostatic balance is reached. TG is determined by prothrombin conversion and thrombin inactivation. These processes can be quantified using the computational thrombin dynamics (TD) add-on analysis for the TG test. We studied TD parameters in cirrhosis to explore its predictive potential for bleeding and thrombosis. In the current study, 32 CP-A, 22 CP-B and 41 CP-C cirrhosis patients and 20 healthy controls were enrolled. Cirrhosis was predominantly alcohol-related (52%), while viral and metabolic etiologies accounted for 34% and 14% of cases, respectively. Patients receiving anticoagulant therapy were excluded. TG was measured using PPP Reagent Low in the presence and absence of thrombomodulin. TG peak height and velocity index were higher in patients than controls (+20%,p = 0.039 and +70%,p = 0.002), and time-to-peak was shorter (-18%,p < 0.0001). TD parameters were obtained computationally based on TG and coagulation factor data. The amount of prothrombin converted (PC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.